Insider trades
Open-market buys and sales that US company officers, directors and 10% owners file, newest filing first.
| Trade type | ||||||||
|---|---|---|---|---|---|---|---|---|
Janet NapolitanoDirector | Vir BiotechnologyVIR | Open-market sale10b5-1 plan | 06/01 | 06/02 | 3,200 sh | $9.45 | $30,240 | −13.1% |
Brent SabatiniSVP, Chief Accounting Officer | Vir BiotechnologyVIR | Open-market sale10b5-1 plan | 06/01 | 06/02 | 379 sh | $9.45 | $3,581.55 | −0.6% |
Vicki L. SatoDirector | Vir BiotechnologyVIR | Open-market sale10b5-1 plan | 05/01 | 05/04 | 22,000 sh | $10.05 | $221,100 | −2.0% |
Marianne De BackerPresident and CEO | Vir BiotechnologyVIR | Open-market sale10b5-1 plan | 04/06 | 04/07 | 72,559 sh | $9.16 | $664,640.44 | −7.1% |
Vicki L. SatoDirector | Vir BiotechnologyVIR | Open-market sale10b5-1 plan | 04/01 | 04/02 | 22,000 sh | $9.07 | $199,540 | −2.0% |
Brent SabatiniSVP, Chief Accounting Officer | Vir BiotechnologyVIR | Open-market sale10b5-1 plan | 03/23 | 03/24 | 7,711 sh | $9.12 | $70,324.32 | −11.1% |
Vir BiotechnologyVIR | Open-market sale10b5-1 plan | 03/02 | 03/03 | 22,000 sh2 trades | $9.50avg. | $209,096 | −1.9% | |
Vir BiotechnologyVIR | Open-market sale10b5-1 plan | 02/24–02/25 | 02/26 | 3,505 sh2 trades | $9.69avg. | $33,950.46 | −2.2% | |
Vir BiotechnologyVIR | Open-market sale10b5-1 plan | 02/24–02/25 | 02/26 | 16,817 sh2 trades | $9.77avg. | $164,239.01 | −13.0% | |
Vir BiotechnologyVIR | Open-market sale10b5-1 plan | 02/24 | 02/26 | 42,377 sh2 trades | $9.75avg. | $413,277.75 | −3.6% | |
Vir BiotechnologyVIR | Open-market sale10b5-1 plan | 02/24 | 02/26 | 14,762 sh | $9.53 | $140,681.86 | −1.4% | |
Jason O'ByrneEVP & CFO | Vir BiotechnologyVIR | Open-market sale10b5-1 plan | 02/24 | 02/26 | 1,634 sh | $9.53 | $15,572.02 | −1.0% |
Brent SabatiniSVP, Chief Accounting Officer | Vir BiotechnologyVIR | Open-market sale10b5-1 plan | 02/24 | 02/26 | 1,430 sh | $9.53 | $13,627.9 | −2.0% |
Vir BiotechnologyVIR | Open-market sale10b5-1 plan | 02/23 | 02/24 | 19,039 sh | $7.45 | $141,840.55 | −1.8% | |
Mark EisnerEVP and Chief Medical Officer | Vir BiotechnologyVIR | Open-market sale10b5-1 plan | 02/23 | 02/24 | 2,089 sh | $7.45 | $15,563.05 | −1.3% |
Jason O'ByrneEVP & CFO | Vir BiotechnologyVIR | Open-market sale10b5-1 plan | 02/23 | 02/24 | 2,089 sh | $7.45 | $15,563.05 | −1.3% |
Vanina de VerneuilEVP, General Counsel, Corp Sec | Vir BiotechnologyVIR | Open-market sale10b5-1 plan | 02/23 | 02/24 | 4,445 sh | $7.45 | $33,115.25 | −3.3% |
Brent SabatiniSVP, Chief Accounting Officer | Vir BiotechnologyVIR | Open-market sale10b5-1 plan | 02/23 | 02/24 | 1,829 sh | $7.45 | $13,626.05 | −2.5% |
Brent SabatiniSVP, Chief Accounting Officer | Vir BiotechnologyVIR | Open-market sale10b5-1 plan | 02/13 | 02/18 | 1,530 sh | $7.79 | $11,918.7 | −3.1% |
Vicki L. SatoDirector | Vir BiotechnologyVIR | Open-market sale10b5-1 plan | 02/02 | 02/03 | 22,000 sh | $7.71 | $169,620 | −1.9% |